{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:38Z","timestamp":1791449438457,"version":"4.3.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01891-y","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:16:22Z","timestamp":1787904982000},"page":"5069-5084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS)"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero Cascio","family":"Ingurgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Cammarata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele D.","family":"Caposiena Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Dragotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Martora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo R.","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Repetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Rossiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Italian Landscape HS (IL-HS) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"10476","key":"1891_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(24)02475-9.","journal-title":"Lancet"},{"issue":"2","key":"1891_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GB Jemec","year":"2012","unstructured":"Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158\u201364. https:\/\/doi.org\/10.1056\/NEJMcp1014163.","journal-title":"N Engl J Med."},{"issue":"5","key":"1891_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899\u2013941. https:\/\/doi.org\/10.1111\/jdv.20472.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1891_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2010.07.010.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1891_CR5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","volume":"76","author":"\u0141 Matusiak","year":"2017","unstructured":"Matusiak \u0141, Szcz\u0119ch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.042.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1891_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523\u201332. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212127.","journal-title":"Ann Rheum Dis"},{"issue":"10443","key":"1891_CR7","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(24)00101-6.","journal-title":"Lancet"},{"issue":"5","key":"1891_CR8","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139. https:\/\/doi.org\/10.1111\/bjd.15748.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1891_CR9","doi-asserted-by":"publisher","first-page":"adv00364","DOI":"10.2340\/00015555-3724","volume":"101","author":"PK Krajewski","year":"2021","unstructured":"Krajewski PK, Matusiak \u0141, von Stebut E, et al. Pain in hidradenitis suppurativa: a cross-sectional study of 1795 patients. Acta Derm Venereol. 2021;101(1):adv00364. https:\/\/doi.org\/10.2340\/00015555-3724.","journal-title":"Acta Derm Venereol."},{"issue":"3","key":"1891_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1891_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989\u201394. https:\/\/doi.org\/10.1111\/jdv.13216.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1891_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","volume":"37","author":"T Tzellos","year":"2023","unstructured":"Tzellos T, van Straalen KR, Kyrgidis A, et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(2):395\u2013401. https:\/\/doi.org\/10.1111\/jdv.18632.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1891_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333. https:\/\/doi.org\/10.1159\/000365390.","journal-title":"Dermatology"},{"issue":"5","key":"1891_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med"},{"issue":"7","key":"1891_CR15","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1111\/ajd.14339","volume":"65","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Pons-Benavent M, Fern\u00e1ndez-Crehuet P, et al. Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: an ambispective observational study. Australas J Dermatol. 2024;65(7):e198\u2013202. https:\/\/doi.org\/10.1111\/ajd.14339.","journal-title":"Australas J Dermatol"},{"issue":"11","key":"1891_CR16","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1007\/s13555-025-01521-z","volume":"15","author":"M Mansilla-Polo","year":"2025","unstructured":"Mansilla-Polo M, Garc\u00eda-Moronta C, Fern\u00e1ndez-Crehuet P, et al. Long-term effectiveness and safety of bimekizumab in patients with moderate to severe hidradenitis suppurativa under real clinical practice conditions: the importance of combined treatment in Hurley III patients and potential factors associated with complete response. Dermatol Ther (Heidelb). 2025;15(11):3267\u201383. https:\/\/doi.org\/10.1007\/s13555-025-01521-z.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1891_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279\u201388. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2905.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01891-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:29Z","timestamp":1791446429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01891-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1891"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01891-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, Boehringer Ingelheim, Almirall, UCB and Difa Cooper. Ruggero Cascio Ingurgio has been a consultant for UCB. Luciano Ibba has been a consultant and\/or speaker and has served as an advisory board member for Almirall and LEO Pharma. Mario Valenti is an Editorial Board Member of\n                      Dermatology and Therapy\n                      . Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Raffaele Dante Caposiena Caro has received honoraria for participation in speaker bureaus from Novartis, Eli Lilly, Sanofi and Pfizer. Andrea Carugno has been a consultant and\/or speaker for AbbVie, Leo Pharma, Eli Lilly, Novartis, Janssen-Cilag, Amgen, Almirall, UCB Pharma and Boehringer Ingelheim. Claudio Marasca has served as a consultant and participated in advisory boards for AbbVie, UCB, Sanofi-Regeneron, Almirall, DAMOR, Novartis, Eli Lilly, MBS and Pfizer. Piergiorgio Malagoli has been a speaker for AbbVie, Eli Lilly, Novartis, Janssen-Cilag, Celgene, Leo Pharma and Almirall. Fabrizio Martora has acted as a speaker for Novartis and UCB. Angelo V. Marzano reports consultancy\/advisory board disease-relevant honoraria from AbbVie, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Galderma, Incyte, Johnson & Johnson, Leo Pharma, MSD, Novartis, Otsuka, Pfizer, Sanofi, Takeda and UCB. Matteo Megna has acted as a speaker or consultant for Almirall, AbbVie, Amgen, Eli Lilly, Leo Pharma, Bristol Myers Squibb, Janssen, Novartis and UCB. Giovanni Paolino has received speakers\u2019 honoraria from AbbVie, Janssen, UCB and Pierre Fabre Pharma. Emanuele Trovato has acted as a speaker or consultant for Almirall, AbbVie, Amgen, Eli Lilly, Leo Pharma, Bristol Myers Squibb, Janssen, Novartis and UCB. Simone Ribero has served as an advisory board member and\/or consultant and has received fees and speaker\u2019s honoraria or has participated in clinical studies for AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer and Sanofi Genzyme. Antonio Costanzo has served as an advisory board member and consultant, and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme and UCB Pharma. Alessandra Narcisi has served on advisory boards and received honoraria for lectures and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme Amgen, and Boehringer Ingelheim. Edoardo Cammarata, Martina Dragotto, Francesco Messina, Alessandra Michelucci, Chiara Moltrasio, Santo Raffaele Mercuri, Federica Repetto, Luigi Rossiello, Nicola Zerbinati and Valentina Dini have nothing to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempted from institutional review board approval as the protocol did not deviate from standard clinical practice. All patients received bimekizumab according to routine clinical practice and the approved prescribing information in Italy. All included patients had provided written informed consent for the retrospective use of anonymized clinical data collected during routine clinical practice. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}